As shown in Fig. 6a–d, Supplementary Figs. 6a, b and 7a, b, OTUD1 promoted sphere formation and anchorage-independent growth in soft agar, while the promoting effect was significantly compromised by administration of IN-8, SP600125, selonsertin or ibrutinib, as determined by the downregulated expression of key CSC genes and reduced CSC content (Fig. 6e–g, Supplementary Figs. 6c and 7c), indicating that targeting the ASKI/JNK pathway is a potential therapeutic strategy for OTUD1high ovarian cancer. This evidence concerns the gene OTUD1 and ovarian carcinoma.